Renaissance Technologies LLC Sells 151,095 Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)

Renaissance Technologies LLC trimmed its position in shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) by 25.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 442,200 shares of the company’s stock after selling 151,095 shares during the quarter. Renaissance Technologies LLC owned approximately 1.32% of Reneo Pharmaceuticals worth $668,000 at the end of the most recent quarter.

Separately, Marquette Asset Management LLC purchased a new position in Reneo Pharmaceuticals during the first quarter valued at $122,000. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Reneo Pharmaceuticals

In related news, major shareholder Braden Michael Leonard purchased 171,339 shares of Reneo Pharmaceuticals stock in a transaction on Tuesday, August 13th. The stock was acquired at an average price of $1.39 per share, for a total transaction of $238,161.21. Following the completion of the transaction, the insider now directly owns 2,843,533 shares in the company, valued at $3,952,510.87. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders acquired 256,239 shares of company stock valued at $355,105. Insiders own 17.90% of the company’s stock.

Reneo Pharmaceuticals Price Performance

RPHM opened at $1.82 on Wednesday. Reneo Pharmaceuticals, Inc. has a 1 year low of $0.98 and a 1 year high of $9.21. The stock has a 50-day moving average price of $1.50 and a 200-day moving average price of $1.59. The firm has a market cap of $60.83 million, a PE ratio of -0.84 and a beta of 0.21.

Reneo Pharmaceuticals (NASDAQ:RPHM) last issued its earnings results on Tuesday, August 13th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. As a group, sell-side analysts anticipate that Reneo Pharmaceuticals, Inc. will post -0.65 EPS for the current year.

Reneo Pharmaceuticals Profile

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.